Login
Subscribe
Email preferences
Sign In
Subscribe
Login
Email preferences
Sign In
Search Portfolio Adviser
Search sponsored by
News
People Moves
Product News
Regulation
M&A
Regulation
Companies
Macroeconomics
Governance
Analysis
Research
Interviews
Macroeconomics
Opinion
ESG
Investment
Open-ended funds
Investment Trusts
ETF
Equities
Emerging markets
Fixed Income
Credit
Government Bonds
Mixed Asset
Alternatives
Private markets
Property
Commodities
Multi-asset
Video
PA Plus
Fund In Five
Events
Magazines
News
News
People Moves
M&A
Regulation
Companies
Macroeconomics
Governance
Top story
Ashmore launches Emerging Markets Frontier Blended Debt fund
17 December 2024
Recent
Inflation rises to 2.6% as fuel prices mount
18 December 2024
Quilter Cheviot selects Nick Wood as head of regional offices
17 December 2024
Analysis
Analysis
Interviews
Macroeconomics
Opinion
ESG
Top story
The key questions for asset allocators in the year ahead
17 December 2024
Recent
The undervalued markets where managers are diversifying away from the US
19 December 2024
How do asset managers logistically prepare for major events?
18 December 2024
Investment
Investment
Open-ended funds
Investment Trusts
ETF
Equities
Emerging markets
Fixed Income
Credit
Government Bonds
Mixed Asset
Alternatives
Private markets
Property
Commodities
Multi-asset
Top story
Hidden gems: Three below-radar funds in the IA Targeted Absolute Returns
19 December 2024
Video
Video
PA Plus
Fund In Five
Top story
Back of the NAV Season 2: Episode 10
20 December 2024
Recent
South West Congress 2024: Interview with Aegon’s Colin Finlayson
16 December 2024
Bitesize: Why now for global small caps
12 December 2024
Events
Magazines
Search
Search sponsored by
Search Portfolio Adviser
Search
AstraZeneca
AstraZeneca shares up 16 despite Pfizer knockback
US drug giant tries again
|
28 April 2014
|
2 minutes
Previous Page
1
2
